Pfizer Inc.
Explore Pfizer
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
3 leaders · Full leadership timeline
Pfizer has repeatedly reinvented itself around new therapeutic waves, from industrial fermentation and penicillin to Lipitor, vaccines, COVID products, and now oncology. The 2025 profile is not a pandemic windfall story; it is a large pharmaceutical company trying to rebuild a durable growth base.
Pfizer operates a prominent, volume-driven biopharmaceutical model. It relies entirely on large scale. The company does not simply rely on slow internal R&D; it operates as a substantial M&A engine, aggressively acquiring smaller biotech firms that have promising drugs, and then using its unparalleled global manufacturing and sales force to maximize the commercial revenue before the patents expire.
Chairman and Chief Executive Officer
Led Pfizer through the COVID vaccine era, the post-pandemic reset, and the Seagen oncology acquisition.
Chief Financial Officer and Executive Vice President
Leads finance, capital allocation, cost discipline, and balance sheet management.
Chief Scientific Officer and President, Research & Development
Leads Pfizer research and development strategy across therapeutic areas.
Pfizer faces patent expirations, Medicare price negotiation, generic and biosimilar competition, R&D productivity pressure, integration risk from Seagen, COVID product normalization, and debt reduction after major dealmaking.